UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 624

Sortiert nach

Effects of protein aggregates: an immunologic perspective

The AAPS journal, 2006-08, Vol.8 (3), p.E501-E507

Rosenberg, Amy S

2006

Volltextzugriff (PDF)

Immunogenicity assessment during the development of protein therapeutics

Journal of pharmacy and pharmacology, 2018-05, Vol.70 (5), p.584-594

2018

Volltextzugriff (PDF)

Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins

Trends in biotechnology (Regular ed.), 2018-10, Vol.36 (10), p.1068-1084

2018

Volltextzugriff (PDF)

Immune-mediated pathology in Duchenne muscular dystrophy

Science translational medicine, 2015-08, Vol.7 (299), p.299rv4

2015

Volltextzugriff (PDF)

Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation

Frontiers in immunology, 2020-05, Vol.11, p.1131-1131

2020

Volltextzugriff (PDF)

Editorial: Induction of immune tolerance: addressing unmet medical need in immune mediated diseases and immune responses to biologics

Frontiers in immunology, 2023-08, Vol.14, p.1219854-1219854

2023

Volltextzugriff (PDF)

Elimination of Antibodies to Recombinant Enzyme in Pompe's Disease

The New England journal of medicine, 2009-01, Vol.360 (2), p.194-195

2009

Volltextzugriff (PDF)

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies

mAbs, 2024, Vol.16 (1), p.2333729-2333729

2024

Volltextzugriff (PDF)

Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort

Frontiers in immunology, 2020-08, Vol.11, p.1727

2020

Volltextzugriff (PDF)

Editorial: Immunogenicity of Proteins Used as Therapeutics

Frontiers in immunology, 2020-10, Vol.11, p.614856-614856

2020

Volltextzugriff (PDF)

Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease

Frontiers in immunology, 2023, Vol.14, p.1301912-1301912

2023

Volltextzugriff (PDF)

Novel reference genes in colorectal cancer identify a distinct subset of high stage tumors and their associated histologically normal colonic tissues

BMC medical genetics, 2019-08, Vol.20 (1), p.138-138, Article 138

2019

Volltextzugriff (PDF)

NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced Genes

Frontiers in immunology, 2020-03, Vol.11, p.224-224

2020

Volltextzugriff (PDF)

Regulatory T cells in γ irradiation-induced immune suppression

PloS one, 2012-06, Vol.7 (6), p.e39092-e39092

2012

Volltextzugriff (PDF)

Lessons learned: new insights on the role of cytokines in COVID-19

Nature immunology, 2021-04, Vol.22 (4), p.404

2021

Volltextzugriff (PDF)

The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge

Nature immunology, 2020-10, Vol.21 (10), p.1146

2020

Volltextzugriff (PDF)

A Novel Function of RNAs Arising From the Long Terminal Repeat of Human Endogenous Retrovirus 9 in Cell Cycle Arrest

Journal of Virology, 2013-01, Vol.87 (1), p.25-36

2013

Volltextzugriff (PDF)

Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review

Annals of translational medicine, 2019-07, Vol.7 (13), p.285-285

2019

Volltextzugriff (PDF)

Managing uncertainty: A perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins

Journal of pharmaceutical sciences, 2012-10, Vol.101 (10), p.3560-3567

2012

Volltextzugriff (PDF)

The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease

Clinical immunology (Orlando, Fla.), 2020-10, Vol.219, p.108541-108541, Article 108541

2020

Volltextzugriff (PDF)

Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans

Blood, 2007-07, Vol.110 (2), p.501-508

2007

Volltextzugriff (PDF)

Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction

Genetics in medicine, 2021-05, Vol.23 (5), p.845-855

2021

Volltextzugriff (PDF)

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease

Genetics in medicine, 2012-01, Vol.14 (1), p.135-142

2012

Volltextzugriff (PDF)

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

Genetics in medicine, 2011-08, Vol.13 (8), p.729-736

2011

Volltextzugriff (PDF)

1 – 25 von 624

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(519)
Mit Volltextzugriff
(549)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(624)
Japanisch
(72)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(22)
Poets & Writers
(16)
The New England Journal Of Medicine
(16)
The Journal Of Immunology
(13)
Cancer Research
(12)
Journal Of Clinical Oncology
(11)
Molecular Genetics And Metabolism
(11)
Psychology Today
(9)
Clinical Cancer Research
(8)
Genetics In Medicine
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Effects of protein aggregates: an immunologic perspective

Immunogenicity assessment during the development of protein therapeutics

Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins

Immune-mediated pathology in Duchenne muscular dystrophy

Lessons Learned to Date on COVID-19 Hyperinflammatory Syndrome: Considerations for Interventions to Mitigate SARS-CoV-2 Viral Infection and Detrimental Hyperinflammation

Editorial: Induction of immune tolerance: addressing unmet medical need in immune mediated diseases and immune responses to biologics

Elimination of Antibodies to Recombinant Enzyme in Pompe's Disease

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies

Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort

Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT

Editorial: Immunogenicity of Proteins Used as Therapeutics

Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease

Novel reference genes in colorectal cancer identify a distinct subset of high stage tumors and their associated histologically normal colonic tissues

NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced Genes

Regulatory T cells in γ irradiation-induced immune suppression

Lessons learned: new insights on the role of cytokines in COVID-19

The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge

A Novel Function of RNAs Arising From the Long Terminal Repeat of Human Endogenous Retrovirus 9 in Cell Cycle Arrest

Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review

Managing uncertainty: A perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins

The potential impact of timing of IVIG administration on the efficacy of rituximab for immune tolerance induction for patients with Pompe disease

Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans

Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease

Suchergebnisse filtern